[go: up one dir, main page]

EP4504705A1 - Formes solides de vismodégib - Google Patents

Formes solides de vismodégib

Info

Publication number
EP4504705A1
EP4504705A1 EP23717459.4A EP23717459A EP4504705A1 EP 4504705 A1 EP4504705 A1 EP 4504705A1 EP 23717459 A EP23717459 A EP 23717459A EP 4504705 A1 EP4504705 A1 EP 4504705A1
Authority
EP
European Patent Office
Prior art keywords
vismodegib
solid form
ppm
theta
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23717459.4A
Other languages
German (de)
English (en)
Inventor
Michal HEGEDUS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon BV filed Critical Synthon BV
Publication of EP4504705A1 publication Critical patent/EP4504705A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom

Definitions

  • the invention relates to solid forms of Vismodegib and to processes for preparation thereof.
  • This invention relates to solid forms of Vismodegib, compound of formula (1) and processes for preparation thereof,
  • Vismodegib 2-Chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methanesulfonyl) benzamide, is a small molecule systemic hedgehog antagonist. Vismodegib was approved for the treatment of patients with advanced basal cell carcinoma for whom surgery is considered inappropriate.
  • Vismodegib was disclosed in W02006028958 application. Solid form of Vismodegib is described in WO2014147504 or WO2014195977 application.
  • An article published as Org. Process Res. Dev. 2016, 20, 1509-1519 described a process for preparation of Vismodegib and a solid form thereof, Form B.
  • the solid Form B prepared according to the process described in the article contains methyl isobutyl ketone, solvent used for preparation of the solid form, on levels 2000 ppm. Such high level might be inacceptable for the product used for a treatment.
  • Prior art there describes no process for preparation of solid Form B containing less than 550 ppm of methyl isobutyl ketone.
  • Solid form of a salt can have improved properties such as solubility, purity or stability that is requested when they are incorporated into a final formulation such as tablets or capsules. There is therefore still a need for solid forms of Vismodegib having improved properties such as a low content of solvent(s).
  • the presented invention relates to a process for preparation of solid form B of Vismodegib.
  • the presented invention also relates to solid form S of Vismodegib and to a process for preparation thereof.
  • the presented invention further relates to solid form M of Vismodegib and to a process for preparation thereof.
  • Solid forms of Vismodegib of the presented invention show excellent crystallinity, purity and stability.
  • Solid forms of Vismodegib of the presented invention preferably the solid Form B of Vismodegib, more preferably the solid Form B prepared according to the presented invention, contain less than 550 ppm, preferably less than 500 ppm or 450 ppm or 400 ppm or 350 ppm or 300 ppm or 250 ppm or 200 ppm of methyl isobutyl ketone.
  • Figure 1 depicts the X-Ray Powder Diffractogram (XRPD) of solid form of Vismodegib, Form S, prepared according to Example 1
  • Figure 2 depicts the DSC pattern of solid form of Vismodegib, Form S, prepared according to Example 1
  • Figure 3 depicts the TGA pattern of solid form of Vismodegib, Form S, prepared according to Example 1
  • Figure 4 depicts the X-Ray Powder Diffractogram (XRPD) of solid form of Vismodegib, Form M, prepared according to Example 2
  • Figure 1 depicts the X-Ray Powder Diffractogram (XRPD) of solid form of Vismodegib, Form B, prepared according to Example 3 or 4 or 5
  • the presented invention relates to a solid form of Vismodegib, Form S and to a process for preparation thereof.
  • the presented invention relates to a process for preparation of solid Form B of Vismodegib comprising subjecting solid Form S of Vismodegib to a temperature between 45°C and 65°C and relative humidity between 80% and 100% for between 2 and 21 days to provide solid Form B of Vismodegib.
  • the solid Form B of the presented invention preferably prepared by the process of the presented invention contains less than 550 ppm, preferably less than 500 ppm or 450 ppm or 400 ppm or 350 ppm or 300 ppm or 250 ppm or 200 ppm of methyl tert-butyl ether.
  • the presented invention further relates to a process for preparation of solid Form B of Vismodegib comprising: a. Mixing the solid Form S of Vismodegib with water; b. Stirring the mixture at a temperature between 85°C and 100°C for between 1.5 and 5 hours.
  • the concentration of solid Form S in water can be between 0.08 g/ml and 0.12 g/ml.
  • the mixture is stirred at temperature between 85°C and 100°C for between 1.5 and 5 hours.
  • the mixture is cooled to a temperature between 20°C and 25°C, obtained suspension is filtered off and obtained solid can be optionally dried.
  • the presented invention further relates to a process for preparation of solid Form B of Vismodegib comprising: a. Mixing the solid Form S of Vismodegib with water; b. Stirring the mixture at a temperature between 15°C and 35°C for between 1.5 and 5 hours.
  • the process can be optionally performed under a protective atmosphere for example under nitrogen or argon.
  • concentration of solid Form S in water can be between 8 g/ml and 16 g/ml.
  • the mixture is stirred at temperature between 15°C and 35°C for between 1.5 and 5 hours. Obtained suspension is filtered off and obtained solid can be optionally dried for example at a temperature between 40°C and 60°C for between 2 and 10 hours.
  • the solid Form B obtained by the process contains less than 550 ppm, preferably less than 500 ppm or 450 ppm or 400 ppm or 350 ppm or 300 ppm or 250 ppm or 200 ppm of methyl tert-butyl ether.
  • the solid Form S can be characterized by XRPD pattern having 20 values 17.3°, 20.7° and 21.8° degrees 2 theta ( ⁇ 0.2 degrees 2 theta).
  • the solid Form S can be also characterized by XRPD pattern having 20 values 10.0°, 11.6°, 17.3°, 19.0°, 20.7° and 21.8° degrees 2 theta ( ⁇ 0.2 degrees 2 theta).
  • the solid form can be further characterized by XRPD pattern described in the following table:
  • the solid Form S can be also characterized by XRPD pattern depicted in Figure 1.
  • the solid form can be further characterized by DSC pattern depicted in Figure 2.
  • the solid form can be further characterized by TGA pattern depicted in Figure 3.
  • the solid form S can be prepared by a process comprising: a. Dissolving Vismodegib in methyl isobutyl ketone to obtain a mixture; b. Cooling the mixture to a temperature between -5°C and 5°C at the rate of 2-4 °C/min; c. Isolating the solid form.
  • the concentration of Vismodegib in methyl isobutyl ketone can be between 0.03 g/ml and 0.07 g/ml.
  • Vismodegib is dissolved in methyl isobutyl ketone preferably at a temperature between 90°C and 120°C.
  • the mixture is rapidly (at the rate of 2-4 °C/min) cooled to a temperature between -5°C and 5°C.
  • the mixture is then stirred at a temperature between -5°C and 5 °C for between 1 and 5 hours. Obtained suspension was filtered off and obtained solid can be optionally dried in vacuum to provide solid Form S of Vismodegib.
  • the presented invention also relates to a solid form of Vismodegib, Form M and to a process for preparation thereof.
  • the solid Form M can be characterized by XRPD pattern having 20 values 7.5°, 11.3°and 15.1° degrees 2 theta ( ⁇ 0.2 degrees 2 theta).
  • the solid Form M can be also characterized by XRPD pattern having 20 values 7.5°, 11.3°, 15.1°, 18.2°, 19.1° and 23.3° degrees 2 theta ( ⁇ 0.2 degrees 2 theta).
  • the solid form can be further characterized by XRPD pattern described in the following table:
  • the solid form can be also characterized by XRPD pattern depicted in Figure 4.
  • the solid form M can be prepared by a process comprising: a. Heating the solid Form B of Vismodegib at a rate of 10°C/min to a temperature between 185°C and 187°C; b. Keep at this temperature for between 5 and 10 minutes.
  • the solid forms of presented invention can be used in a pharmaceutical composition for the treatment of conditions treatable by Vismodegib or a salt thereof.
  • Nuclear magnetic resonance spectroscopy was performed using Avance III 400 MHz NMR spectrometer.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des formes solides de vismodégib, un composé de formule (1) et des procédés de préparation de ceux-ci.
EP23717459.4A 2022-04-05 2023-04-03 Formes solides de vismodégib Pending EP4504705A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22166755 2022-04-05
PCT/EP2023/058668 WO2023194300A1 (fr) 2022-04-05 2023-04-03 Formes solides de vismodégib

Publications (1)

Publication Number Publication Date
EP4504705A1 true EP4504705A1 (fr) 2025-02-12

Family

ID=81328350

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23717459.4A Pending EP4504705A1 (fr) 2022-04-05 2023-04-03 Formes solides de vismodégib

Country Status (2)

Country Link
EP (1) EP4504705A1 (fr)
WO (1) WO2023194300A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1789390B1 (fr) 2004-09-02 2011-11-09 Genentech, Inc. Inhibiteurs pyridyles de la signalisation hedgehog
US9278932B1 (en) 2013-03-22 2016-03-08 Shilpa Medicare Limited Process for preparation of 2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide solid forms
WO2014195977A2 (fr) 2013-06-05 2014-12-11 Hetero Research Foundation Nouveaux polymorphes de vismodegib
WO2015169269A1 (fr) * 2014-05-05 2015-11-12 Zentiva, K.S. Sels de 2-chloro-n- (4-chloro -3- (pyridin -2-yl)phényl)-4- (méthylsulfonyl)benzamide

Also Published As

Publication number Publication date
WO2023194300A1 (fr) 2023-10-12

Similar Documents

Publication Publication Date Title
EP0548114B1 (fr) Monohydrate de furoate de mometasone, son procede de fabrication et compositions pharmaceutiques
US20080182988A1 (en) Aripiprazole crystalline forms
US20080085903A1 (en) Novel crystalline forms of aripiprazole
US10138239B2 (en) Preparation method of crystalline form a of PCI-32765
EP2173718A2 (fr) Procédé d'isolement et de purification du montélukast
EP3201190A1 (fr) Forme cristalline de dimaléate d'afatinib
EP4520760A1 (fr) Forme cristalline de lurbinectédine et son procédé de préparation
AU2019370926B2 (en) Novel salt of a Bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same
EP4486725A1 (fr) Sel de cabozantinib à l'acide l (+) tartrique et ses formes solides
EP4504705A1 (fr) Formes solides de vismodégib
EP3573958A1 (fr) Formes cristallines d'éluxadoline et leurs procédés de préparation
EP2825525B1 (fr) Nouvelle forme polymorphe d'un agoniste du récepteur adrénergique bêta-2 à action prolongée
US10913721B2 (en) Crystalline form of aripiprazole
EP2251318B1 (fr) Méthode de production de fumarate de fésotérodine
EP4069668A1 (fr) Formes cristallines de sel de sodium d'acide bempédoïque
WO2015062562A1 (fr) Polymorphe stable du sel de (2r)-4-oxo-4-[3-(trifiuorométhyl)-5,6- dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8h)-yl]-1-(2,4,5-trifluorophényl)butan-2-amine avec du l-acide tartrique
EP3604292A1 (fr) Procédé de préparation de forme quinoïde de fluorescéine
JP7704835B2 (ja) ビランテロールトリフェナテートの精製方法
US11358966B2 (en) Pyridine or N,N-dimethyl acetamide solvated solid state forms of solvated idelalisib, their use and preparation
KR102026337B1 (ko) 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
WO2023020762A1 (fr) Formes cristallines d'un produit d'addition de tafamidis nicotinamide
EP3052499B1 (fr) Monohydrate de chlorhydrate d'abacavir de forme cristalline et procédé pour sa préparation
EP2938617B1 (fr) Procédé pour la préparation de trihydrate de méropénème
WO2004087688A1 (fr) Nouvelles formes cristallines de gatifloxacine
US20240199642A1 (en) Method for obtaining rifapentine with a new crystalline form

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20241105

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: APP_12119/2025

Effective date: 20250312

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)